This observation together with the results obtained by the ex vivo experiments and the fact that CPscore determined response to neoadjuvant doxorubicin would indicate that PP2A activation is able to overcome doxorubicin resistance in breast cancer cells. The gene discussed is PTPA; the disease is breast cancer.